---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040033"
form_type: "8-K"
ticker: "LFST"
cik: "0001845257"
company_name: "LifeStance Health Group, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T23:22:06.981541+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LifeStance Q2 revenue up 24% to $259.6M; raises FY revenue guidance to $1.01-1.04B

## Summary
- Q2 revenue $259.6M (+24% YoY); net loss $45.5M improved from $68.7M loss.
- Adjusted EBITDA $14.1M (-3% YoY); Center Margin $73.0M (28.1% of revenue).
- Total clinicians 6,132 (+17% YoY); net add 171 in Q2.
- FY 2023 revenue guidance raised to $1.01-1.04B; reaffirms Adj. EBITDA $50-62M.
- Q3 2023 guidance: revenue $250-260M, Adj. EBITDA $11-17M.

## SEC filing metadata
- accession: 0000950170-23-040033
- form_type: 8-K
- ticker: LFST
- cik: 0001845257
- company_name: LifeStance Health Group, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845257/000095017023040033/0000950170-23-040033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845257/000095017023040033/lfst-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040033
- JSON: https://secwatch.observer/filing/0000950170-23-040033.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040033.txt

## Key facts
- Earnings Releases
  LifeStance Health Group, Inc. reported second quarter ended June 30, 2023 results: revenue $259.6 million, net income $45.5 million. Guidance raised.
  - Period: second quarter ended June 30, 2023
  - Revenue: $259.6 million
  - Net income: $45.5 million
  - Guidance: raised
  - Result: reported results
  source text: the second quarter ended June 30, 2023. (All results compared to prior-year comparative period, unless otherwise noted) Q2 2023 Highlights and FY 2023 Outlook • Total revenue of $259.6 million increased $50.1 million or 24% compared to total revenue of $209.5 million • Total clinicians of 6,132 up 17%, a sequential net increase of 171 in the second quarter • Net loss
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845257/000095017023040033/0000950170-23-040033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.